Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment

被引:64
作者
Bishop, JR
Ellingrod, VL
Moline, J
Miller, D
机构
[1] Univ Iowa, Coll Pharm, Clin & Adm Div, Iowa City, IA 52242 USA
[2] Univ Iowa, Carver Coll Med, Dept Psychiat, Iowa City, IA 52242 USA
关键词
metabotropic; glutamate; antipsychotic; olanzapine; pharmacogenetics; schizophrenia;
D O I
10.1016/j.schres.2005.04.001
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Purpose: The excitatory neurotransmitter glutamate has become an important area of focus for schizophrenia researchers. Polymorphisms in the type-three metabotropic glutamate receptor gene (GRM3) have been associated with the pathogenesis of schizophrenia. The purpose of this study was to determine whether a pharmacogenetic relationship exists between six polymorphisms of GRM3 and clinical improvement during olanzapine treatment in persons with schizophrenia. Method: Forty-two subjects meeting DSM-IV criteria for schizophrenia started olanzapine and were titrated to a fixed dose of 7.5-20 mg/day for 6 weeks. The Brief Psychiatric Rating Scale (BPRS) total score and the Scale for Assessment of Negative Symptoms (SANS) were completed at baseline and then weekly to assess psychopathology. Results: The principle finding of this study is that GRM3 polymorphisms were collectively significant predictors of negative symptom improvement in persons with schizophrenia treated with the atypical antipsychotic olanzapine. After controlling for baseline SANS scores, the genotypes as a whole were significant predictors of negative symptom improvement, accounting for approximately 28% of the variance in scores (F=16.30, df=29, p < 0.001). The single nucleotide polymorphism SNP1 (rs274622), located in a potential promoter region, had the most significant influence on SANS scores, but the effects of this locus could not be fully separated from the other polymorphisms. The mean decrease in SANS scores was 21% vs. 51% for SNP1 T/T+T/C and SNP1C/C subjects, respectively. Conclusion: These data suggest that polymorphisms in the GRM3 gene may be useful as predictors of negative symptom improvement in persons with schizophrenia treated with olanzapine. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:253 / 260
页数:8
相关论文
共 20 条
[1]   ANALYSIS OF OLANZAPINE IN HUMAN PLASMA UTILIZING REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION [J].
CATLOW, JT ;
BARTON, RD ;
CLEMENS, M ;
GILLESPIE, TA ;
GOODWIN, M ;
SWANSON, SP .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1995, 668 (01) :85-90
[2]   Pharmacology and functions of metabotropic glutamate receptors [J].
Conn, PJ ;
Pin, JP .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1997, 37 :205-237
[3]   Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia [J].
Egan, MF ;
Straub, RE ;
Goldberg, TE ;
Yakub, I ;
Callicott, JH ;
Hariri, AR ;
Mattay, VS ;
Bertolino, A ;
Hyde, TM ;
Shannon-Weickert, C ;
Akil, M ;
Crook, J ;
Vakkalanka, RK ;
Balkissoon, R ;
Gibbs, RA ;
Kleinman, JE ;
Weinberger, DR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (34) :12604-12609
[4]   5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia [J].
Ellingrod, VL ;
Perry, PJ ;
Lund, BC ;
Bever-Stille, K ;
Pleming, F ;
Holman, TL ;
Miller, D .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (06) :622-624
[5]   D-cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia [J].
Evins, AE ;
Amico, E ;
Posever, TA ;
Toker, R ;
Goff, DC .
SCHIZOPHRENIA RESEARCH, 2002, 56 (1-2) :19-23
[6]   REGULATION OF CORTICAL AND SUBCORTICAL GLUTAMATE-RECEPTOR SUBUNIT EXPRESSION BY ANTIPSYCHOTIC-DRUGS [J].
FITZGERALD, LW ;
DEUTCH, AY ;
GASIC, G ;
HEINEMANN, SF ;
NESTLER, EJ .
JOURNAL OF NEUROSCIENCE, 1995, 15 (03) :2453-2461
[7]   Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia [J].
Fujii, Y ;
Shibata, H ;
Kikuta, R ;
Makina, C ;
Tani, A ;
Hirata, N ;
Shibata, A ;
Ninomiya, H ;
Tashiro, N ;
Fukumaki, Y .
PSYCHIATRIC GENETICS, 2003, 13 (02) :71-76
[8]   A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia [J].
Goff, DC ;
Tsai, G ;
Levitt, J ;
Amico, E ;
Manoach, D ;
Schoenfeld, DA ;
Hayden, DL ;
McCarley, R ;
Coyle, JT .
ARCHIVES OF GENERAL PSYCHIATRY, 1999, 56 (01) :21-27
[9]   Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine [J].
Goff, DC ;
Hennen, J ;
Lyoo, IK ;
Tsai, G ;
Wald, LL ;
Evins, AE ;
Yurgelun-Todd, DA ;
Renshaw, PF .
BIOLOGICAL PSYCHIATRY, 2002, 51 (06) :493-497
[10]   Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia [J].
Heresco-Levy, U ;
Ermilov, M ;
Shimoni, J ;
Shapira, B ;
Silipo, G ;
Javitt, DC .
AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (03) :480-482